Indicators on BCAT-IN-4 You Should Know
The main end point was the protection and tolerability of sifalimumab. Treatment method-emergent adverse occasions (AEs) and severe AEs (SAEs) as well as their severity, end result, and any relationship into the examine medication had been recorded by the investigator all over the research. AEs were being regarded likely to be relevant to research